Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
German Multicenter EPO Stroke Trial
NCT00604630Phase 3Completed
- Sponsor
- Max Planck Institute for Multidisciplinary Sciences
- Start
- Jan 2003
- Primary completion
- Jun 2008
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Epoetin alfa with Placebo (2 arms). Primary endpoint: Barthel Index at Day 90. Started Jan 2003; status: completed.
02
Drugs
epoetin alfa
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00604630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00604630.